Unsatisfactory results of the SoC treatment for high-grade gliomas have recently led to the development of multiple, highly specific and personalised therapies. Still, however, the majority of the clinical trials have failed to demonstrate efficacy by an improvement in OS. The ho...
JW CreaGene, a subsidiary of JW Shinyak, said Thursday that it has started recruiting patients participating in phase 1/2 clinical trials for CreaVax-BC, a glioblastoma treatment. CreaVax-BC is a therapy that induces Cytotoxic T Lymphocyte (CTL) by in
In particular, we discuss how treatment regimens based on single antigen peptide vaccines evolved into fully personalised, polyvalent cell-based vaccines, CAR-T cell, and viral or gene therapies. Furthermore, the results of the most influential clinical trials and a selection of innovative ...